Glenmark Pharma News

Voting result as required under Regulation 44(3) of SEBI Listing Regulations and Scrutinizers Report is enclosed.

Allotment of Equity Shares under the Glenmark Pharmaceuticals Limited Employee Stock Option Scheme, 2016

Glenmark Pharmaceuticals Inc., USA to launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg

Indian pharmaceutical companies are crucial to the U.S. healthcare system, filling four out of every ten prescriptions in 2022. Reports indicate that Indian medicines saved the U.S. healthcare system USD 219 billion in 2022 and USD 1.3 trillion from 2013 to 2022. Over the next five years, Indian generics are expected to contribute an additional USD 1.3 trillion in savings.

Glenmark's marketing portfolio as of December 2024 had 201 generic products authorised for distribution in the US. The company has 51 applications pending at various stages in the approval process.

Appointment of Senior Management Personnel of the Company

When it is Trump, logic usually flies out of the window. There is, indeed, little that is logical about the reciprocal tariffs he has announced. Yet, we were right in our very logical assumption that, because the US cannot afford to hit its broken healthcare system further, it would not impose any tariff on imports of pharmaceuticals. Pharma has indeed been exempted from the swathe of tariffs imposed by Trump. But that’s not the end of the story. We don’t know if sectoral sanctions will come up. More importantly, China, a key player in the global pharma space as it produces critical APIs, might try to act smart. So, you can be bullish about pharma stocks, but be very selective.

Shares of Indian pharma companies with significant US exposure surged by up to 14% after President Trump refrained from imposing new tariffs on the sector. While electronics and gems are hit by tariffs, pharmaceuticals remain exempt, boosting companies like Gland Pharma and Aurobindo Pharma.

Glenmark Pharmaceuticals Inc., USA launches Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-Dose Vial)

Disclosure under Regulation 30 of SEBI LODR Regulations, 2015

Nomura, BNP Paribas, and HSBC have issued updated recommendations on Shree Cement, Larsen & Toubro (L&T), and Glenmark Pharma, emphasizing potential upside opportunities for investors.

Analysts recommend stocks such as HDFC Bank, Glenmark Pharmaceuticals, Tata Steel, and Samvardhana Motherson, expecting returns between 17% and 27%. Improvements in growth, favorable risk-reward, valuation comfort, and positive market outlooks drive their optimistic projections.

Technical analysis identifies select stocks that may gain momentum even in volatile markets. Picks by the technical charts today.

Newspaper Advertisement of Postal Ballot Notice

Intimation regarding Postal Ballot Notice

Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%

Glenmark Pharma Expands Cardiometabolic Portfolio with the Launch of Empagliflozin and its Fixed - Drug Combinations in India

Glenmark Therapeutics Inc., Polyethylene Glycol 3350

Glenmark share price: The recall affects around 14.76 lakh bottles of Atomoxetine Capsules in various strengths, produced by Glenmark Pharmaceuticals Inc., USA, a subsidiary of the Mumbai-based pharmaceutical company.

Glenmark Pharmaceuticals Inc., USA acquires and launches Acetylcysteine Injection, 6 gm/30mL (200mg/mL) Single-Dose Vials

Mahindra & Mahindra is working to scale up some of its smaller businesses to match its portfolio of multiple large companies, the top executive at the tractor-to-technology group told ET.

Details of Analyst/Institutional Investor Meeting is enclosed

Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 10 mg/ 10 mL (1 mg/mL) Multiple-Dose Vial

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015: Glenmark Pharmaceuticals Ltd. (hereinafter referred as "the Company")

ICICI Securities maintains a Reduce call on Glenmark Pharmaceuticals with a target price of Rs 1,265. The current market price is Rs 1365.9. Glenmark’s US prospects may improve from H2FY26. The company plans product launches and strategic initiatives to address supply and financial challenges in the coming years. They report a net profit of Rs 348.

Further to our letter dated 5th February, 2025 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (LODR), Regulations 2015, the transcript of the Earnings Call held on Monday, 17th February, 2025 for the third quarter ended December 31, 2024 has been uploaded on the Company''s website.

Dr. Reddy’s Laboratories fell 5.8% to Rs 1,128.90, while Zydus Lifesciences dropped 4.8%. Sun Pharma, India's largest drugmaker, declined by 3.2% to Rs 1,647.35, becoming the top loser on the BSE Sensex and one of the top five decliners on the Nifty 50.

Details of Analyst / Institutional Investor meeting is enclosed.